| Efficacy and Safety of Rechallenge with BRAF/MEK Inhibitors in Advanced Melanoma Patients: A Systematic Review and Meta-Analysis JN Priantti, M Vilbert, T Madeira, FCA Moraes, ECK Hein, A Saeed, ... Cancers 15 (15), 3754, 2023 | 14 | 2023 |
| Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis I Michelon, M Vilbert, AD Marinho, CER Castro, MI Dacoregio, C Stecca, ... ESMO open 9 (2), 102233, 2024 | 9 | 2024 |
| Cyclin-dependent kinase 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone for HR-positive, HER-2-negative early breast cancer: meta-analysis of phase III … FCA Moraes, G de Oliveira Almeida, VFC Alves, JN Priantti, GC Gomes, ... Journal of Personalized Medicine 14 (5), 464, 2024 | 5 | 2024 |
| Updated pooled analyses of first-line anti-PD1/PD-L1 inhibitors plus chemotherapy in advanced esophageal squamous cell carcinoma. M Vilbert, JN Priantti, T Madeira, FCA Moraes, A Tojjari, IH Sahin, ... Journal of Clinical Oncology 42 (3_suppl), 366-366, 2024 | 2 | 2024 |
| 1853P Effect of logotherapy on anxiety in patients with cancer: A systematic review and meta-analysis DC Barroso, TM Madeira, AD Marinho, AV Teixeira Filho, MAA Freitas, ... Annals of Oncology 34, S1002, 2023 | 2 | 2023 |
| Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: a systematic review and meta-analysis JN Priantti, M Vilbert, FCA de Moraes, T Madeira, EM de Lima Santiago, ... Cancers 16 (14), 2611, 2024 | 1 | 2024 |
| Mesenchymal–Epithelial Transition Kinase Inhibitor Therapy in Patients with Advanced Papillary Renal-Cell Carcinoma: A Systematic Review and Meta-Analysis FCA Moraes, M Vilbert, VFC Alves, G de Oliveira Almeida, JN Priantti, ... International Journal of Molecular Sciences 24 (24), 17582, 2023 | 1 | 2023 |
| 1098P Anti-PD1-based neoadjuvant therapy in resectable stage III or IV melanoma patients: A systematic review and meta-analysis TM Madeira, FCA Moraes, JN Priantti, EM de Lima Santiago, MF Ribeiro, ... Annals of Oncology 34, S661, 2023 | 1 | 2023 |
| 1365P Neurocognitive adverse events related to lorlatinib in non-small cell lung cancer: A systematic review and meta-analysis JN Priantti, FCA Moraes, TM Madeira, EM de Lima Santiago, MS Vilbert Annals of Oncology 34, S784, 2023 | 1 | 2023 |
| Efficacy of Subsequent Treatments After Disease Progression on CDK4/6 Inhibitors in Patients With Hormone Receptor–Positive Advanced Breast Cancer LV Ravani, P Calomeni, M Vilbert, T Madeira, M Wang, D Deng, L Testa, ... JCO Oncology Practice, OP-24-00649, 2024 | | 2024 |
| Torsemide versus Furosemide in the Treatment of Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials L Teixeira, N Felix, DDP Navalha, R Ferreira, MRC Clemente, T Madeira, ... Arquivos Brasileiros de Cardiologia 121, e20230825, 2024 | | 2024 |
| Torsemida em Comparação com Furosemida no Tratamento da Insuficiência Cardíaca: Uma Revisão Sistemática e Metanálise de Ensaios Clínicos Randomizados L Teixeira, N Felix, DDP Navalha, R Ferreira, MRC Clemente, T Madeira, ... Arquivos Brasileiros de Cardiologia 121, e20230825, 2024 | | 2024 |
| Efficacy of subsequent treatments after disease progression on CDK4/6 inhibitors therapy in patients with hormone receptor-positive metastatic breast cancer: A Kaplan-Meier … LV Ravani, P Calomeni, M Vilbert, T Madeira, M Wang, D Deng, L Testa, ... Journal of Clinical Oncology 42 (16_suppl), 1065-1065, 2024 | | 2024 |
| Safety and efficacy of interleukin-6 blockade for immune-related adverse events: A systematic review and meta-analysis. M Vilbert, EC Koch Hein, T Madeira, I Michelon, J N. Priantti, M Lobo, ... Journal of Clinical Oncology 42 (16_suppl), e24149-e24149, 2024 | | 2024 |
| Torsemide versus furosemide in patients with heart failure: a systematic review and updated meta-analysis of randomised controlled trials LMF Teixeira, NS Felix, DDP Navalha, TM Madeira, CF Farias, ... European Heart Journal 44 (Supplement_2), ehad655. 988, 2023 | | 2023 |
| 281P Cyclin-dependent kinase 4/6 inhibitors combined with endocrine therapy for hormonal receptor-positive, human epidermal growth factor receptor 2-negative early breast … VFC Alves, FCA Moraes, GDC Gomes, GDO Almeida, S Carnevalli, ... Annals of Oncology 34, S296, 2023 | | 2023 |
| Efficacy and safety of BRAF/MEK inhibitor rechallenge in patients with advanced melanoma: Systematic review and meta-analysis. JN Priantti, M Vilbert, T Madeira, FCA Moraes, EC Koch Hein, ... Journal of Clinical Oncology 41 (16_suppl), e21535-e21535, 2023 | | 2023 |
| Neoadjuvant versus adjuvant therapy in patients with stage III or IV resectable melanoma: A systematic review and meta-analysis. T Madeira, M Vilbert, JN Priantti, FCA Moraes, EC Koch Hein, MF Ribeiro, ... Journal of Clinical Oncology 41 (16_suppl), e21542-e21542, 2023 | | 2023 |
